<DOC>
	<DOCNO>NCT03026140</DOCNO>
	<brief_summary>In exploratory study , patient stage 1-3 adenocarcinoma colon sign distant metastasis treat short-term immunotherapy + COX2-inhibitors . This treatment give window period surgical resection tumor . The duration treatment approximately 6 week .</brief_summary>
	<brief_title>Nivolumab , Ipilimumab COX2-inhibition Early Stage Colon Cancer : Unbiased Approach Signals Sensitivity</brief_title>
	<detailed_description>In single-center , open-label , exploratory study , investigator enroll 60 patient within two year , include 30 patient MSS tumor 30 patient MSI tumor . Patients MSS tumor randomize either group 1 2 . Patients MSI tumor allocate group 1 . Patients group 1 treat single dose ipilimumab 1mg/kg day 1 two cycle nivolumab 3mg/kg day 1 15 , respectively . Patients group 2 treat single dose ipilimumab 1mg/kg day 1 , two cycle nivolumab 3mg/kg one day 1 15 celecoxib daily day surgery .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Inclusion criterion : Signed write informed consent Patients least 18 year age Stage 13 adenocarcinoma colon Exclusion criterion : No sign distant metastases No sign obstruction macroscopic bleed suspicion perforation Colonoscopy must perform registration obtain studyspecific biopsy . If biopsy possible , patient include study WHO performance status 0 1 No previous treatment immune checkpoint inhibitor target CTLA4 , PD1 PDL1 For patient MSS tumor : current use NSAIDs COX2inhibitors registration active peptic ulcer , gastrointestinal bleeding , unstable ischemic heart disease thrombus etiology significant establish ischemic heart disease , peripheral arterial disease and/or cerebrovascular disease No radiotherapy prior plan postsurgery radiotherapy No history allergy study drug component , severe hypersensitivity reaction monoclonal antibody , allergy severe hypersensitivity NSAIDs COX2I ( MSS tumor ) No intercurrent illness , include limited infection , unstable angina pectoris No positive test hepatitis B virus surface antigen ( HBsAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicate acute chronic infection history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) No autoimmune disease No condition require systemic treatment either corticosteroid ( 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration No live vaccine 4 week prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MSI tumor</keyword>
	<keyword>MSS tumor</keyword>
	<keyword>short-term immunotherapy</keyword>
	<keyword>surgical resection</keyword>
	<keyword>nivolumab</keyword>
	<keyword>ipilimumab</keyword>
</DOC>